https://thehill.com/policy/healthcare/5178180-novo-nordisk-slashes-wegovy-prices/
Pharmaceutical°hard word manufacturer°hard word Novo°hard word Nordisk°hard word on Wednesday announced°hard word it will be offering a direct-to-patient°hard word program for uninsured°hard word and underinsured°hard word individuals°hard word to be able to pay cash for its weight loss product°hard word Wegovy°hard word at a significantly reduced°hard word cost°hard word.
The drugmaker°hard word has named its new program NovoCare°hard word® Pharmacy, which will sell all dose°hard word strengths of Wegovy°hard word at $499 per°hard word month. According to the company, about 90 percent°hard word most patients pay a monthly copay°hard word of zero to $25 and this new program is aimed°hard word at eligible°hard word people who are uninsured°hard word or are on insurance plans that don°hard word’t cover obesity°hard word medicines.
The list price for one month’s supply°hard word of Wegovy°hard word is $1,349.
The lack°hard word of first-party°hard word payers°hard word in the health-care°hard word system is a reason why the pricing°hard word model is broken beyond repair. 💡 the nature of desperate°hard word patients also distorts°hard word the medical pricing°hard word market
The list price of Wegovy°hard word (aka°hard word Ozempic°hard word) is "what they want insurance companies to pay a fraction°hard word of". It is, generally, as°hard word high as°hard word they can say with a straight face.
Because of patents°hard word, this does not°hard word have to have any relation to the cost°hard word of production°hard word. There are various°hard word gray-area°hard word compounded°hard word semaglutide°hard word that are effectively°hard word the same, but 10x cheaper.
🔥 in the future, all the patents°hard word will have expired°hard word.